KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Non-Current Deferred Tax Liability (2016 - 2023)

Historic Non-Current Deferred Tax Liability for Inovio Pharmaceuticals (INO) over the last 15 years, with Q4 2023 value amounting to $2.0 million.

  • Inovio Pharmaceuticals' Non-Current Deferred Tax Liability fell 1508.31% to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.0 million, marking a year-over-year decrease of 1508.31%. This contributed to the annual value of $2.0 million for FY2023, which is 1508.31% down from last year.
  • Inovio Pharmaceuticals' Non-Current Deferred Tax Liability amounted to $2.0 million in Q4 2023, which was down 1508.31% from $32046.0 recorded in Q3 2023.
  • In the past 5 years, Inovio Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $3.0 million in Q4 2021 and a low of $24766.0 during Q1 2019
  • In the last 5 years, Inovio Pharmaceuticals' Non-Current Deferred Tax Liability had a median value of $32046.0 in 2019 and averaged $393235.4.
  • Per our database at Business Quant, Inovio Pharmaceuticals' Non-Current Deferred Tax Liability surged by 925530.18% in 2021 and then plummeted by 2171.45% in 2022.
  • Quarter analysis of 5 years shows Inovio Pharmaceuticals' Non-Current Deferred Tax Liability stood at $32046.0 in 2019, then changed by 0.0% to $32046.0 in 2020, then skyrocketed by 9255.3% to $3.0 million in 2021, then dropped by 21.71% to $2.3 million in 2022, then decreased by 15.08% to $2.0 million in 2023.
  • Its last three reported values are $2.0 million in Q4 2023, $32046.0 for Q3 2023, and $32046.0 during Q2 2023.